MedTrace Logo

Reducing Postoperative Side Effect of Pregabalin

NCT04599894 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-10-26

No results posted yet for this study

Summary

The purpose of this study was to determine 1) if pregabalin, when given 37.5 mg twice on the day before surgery, would be effective in reducing the early postoperative side effects including dizziness, nausea, vomiting and sedation of receiving pregabalin 75mg two hours pre-operatively and 75mg per day until the third postoperative day; and 2) whether this intervention affected the opioids consumption, and independent transfers at six hours post-op, time to readiness for independent transfers, time to readiness for discharge and pain or not.

Conditions

  • Pain, Postoperative
  • Arthroplasty, Replacement, Knee
  • Arthroplasty, Replacement, Hip

Interventions

DRUG

37.5mg Pregabalin + 75mg Pregabalin

37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively

DRUG

75mg Pregabalin

75mg pregabalin postoperatively

Sponsors & Collaborators

  • The First Hospital of Jilin University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-04-30
Completion
2021-05-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04599894 on ClinicalTrials.gov